5 Key Takeaways

• 1

  The study analyzed data from 143,005 patients diagnosed with dry eye disease who initiated lifitegrast therapy between 2017 and 2024.

• 2

  The cohort was predominantly female (80%) with a mean age of 61 years, reflecting diverse geographic and insurance backgrounds.

• 3

  Cataract was the most common ocular comorbidity, while hyperlipidemia and hypertension were the most prevalent nonocular comorbidities.

• 4

  Only 10% of patients had previously used other therapies, indicating a large untreated population in the early stages of DED.

• 5

  Diagnostic testing for dry eye was underutilized, with less than 4% diagnosed with evaporative dry eye based on tear breakup time.